Loading...
•
Jun 30, 2024
ACADIA Q2 2024 Earnings Report
Acadia reported a strong Q2 2024 with significant revenue growth and advancements in clinical trials.
Key Takeaways
Acadia Pharmaceuticals announced a successful second quarter in 2024, marked by a 46% year-over-year increase in total net product sales, driven by growth in both NUPLAZID and DAYBUE sales. The company is also progressing with its Phase 3 trial in Prader-Willi syndrome and Phase 2/Phase 3 program in Alzheimer’s disease psychosis.
Total net product sales reached $242.0 million, a 46% increase year-over-year.
NUPLAZID net sales grew by 11% year-over-year, with a 6% increase in unit sales.
DAYBUE net sales showed an 11% sequential growth.
Acadia is advancing enrollment in Phase 3 trial for Prader-Willi syndrome and Phase 2/Phase 3 program for Alzheimer’s disease psychosis.
Revenue by Segment
Forward Guidance
Acadia is updating its 2024 guidance.
Positive Outlook
- NUPLAZID net product sales guidance is increased to a range of $590 to $610 million from the previous range of $560 to $590 million, reflecting stronger underlying demand driving recent higher unit volume.
- Total revenue guidance is revised to a range of $930 to $980 million from the previous range of $930 million to $1.01 billion.
- R&D expense guidance is narrowed to the lower end of the previous range and is now expected to be between $305 to $315 million.
- SG&A expense guidance is narrowed to the higher end of the previous range and is now expected to be between $465 to $480 million.
Challenges Ahead
- DAYBUE net product sales guidance is decreased to a range of $340 to $370 million from the previous range of $370 to $420 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...